In vivo incorporation of bromodeoxyuridine into proliferating cells in the marrow and its effects on granulocyte-macrophage progenitor cells
Bromodeoxyuridine (BUdR), a potential radiosensitizing drug, was given by intravenous infusion at 650-1000 mg/m2/day for up to 12 days. In vivo incorporation into human bone marrow was assayed by differential chromatid staining as well as by comparison of in vitro radiation survival curves of granulocyte-macrophage progenitor cells scored at both day 7 and day 14. Although a difference was found in the radiation survival of control (untreated) day-7 progenitor cells (Do = 1.39 Gy) and day-14 progenitor cells (Do = 0.89 Gy), a similar degree of in vitro radiosensitization was found for BUdR-treated bone marrow progenitor cells scored at day 7 and day 14. The culture technique provided a bioassay for the in vivo action of BUdR. BUdR treatment produced transient moderate myelosuppression that probably resulted from BUdR incorporation into normal marrow cells.
- Research Organization:
- National Cancer Institute, Bethesda, MD
- OSTI ID:
- 5265428
- Journal Information:
- Exp. Hematol.; (United States), Journal Name: Exp. Hematol.; (United States) Vol. 4; ISSN EXHMA
- Country of Publication:
- United States
- Language:
- English
Similar Records
Continuous intravenous infusions of bromodeoxyuridine as a clinical radiosensitizer
Phase I study of intermittent intravenous bromodeoxyuridine (BUdR) with conventional fractionated irradiation
Related Subjects
63 RADIATION, THERMAL, AND OTHER ENVIRON. POLLUTANT EFFECTS ON LIVING ORGS. AND BIOL. MAT.
ANIMAL CELLS
ANIMAL TISSUES
ANTIMETABOLITES
AZINES
BODY
BONE MARROW
CELL PROLIFERATION
CONNECTIVE TISSUE CELLS
DEOXYURIDINE
DRUGS
HEMATOPOIETIC SYSTEM
HETEROCYCLIC COMPOUNDS
HYDROXY COMPOUNDS
IN VIVO
MACROPHAGES
NUCLEOSIDES
NUCLEOTIDES
ORGANIC COMPOUNDS
ORGANIC NITROGEN COMPOUNDS
ORGANS
PHAGOCYTES
PYRIMIDINES
RADIOSENSITIVITY EFFECTS
RIBOSIDES
SOMATIC CELLS
STEM CELLS
TISSUES
URACILS